Octreotide

FDA-approved product existsPeptideGH axis & hormones

Awaiting review, BioHarmony verdict

Not yet scored. Queued for review; until then rely on the status and sources below.

What is Octreotide?

FDA-approved octreotide products exist for acromegaly and severe diarrhea or flushing associated with specified tumors; dosing and preparation vary by formulation.

Saved on this device only.

Dosing as published

Source-reported figures only. This page does not calculate a personal dose.

Approved labelOctreotide acetate injection prescribing information for acromegaly, carcinoid tumors, and VIPomas
PopulationAdults covered by the approved octreotide indications
DoseAcromegaly starts at 50 mcg three times daily and has a labeled maintenance range of 100-500 mcg three times daily. Carcinoid tumors use 100-600 mcg/day and VIPomas use 200-300 mcg/day in divided doses during the initial 2 weeks.
RouteSubcutaneous or intravenous injection
FrequencyTwo to four divided doses daily depending on indication
DurationLong-term use within the approved indication with response-based adjustment
PreparationReady-to-use 100 mcg/mL or 500 mcg/mL solution in a single-dose vial; no reconstitution.
Source: Dosage and Administration sections 2.1-2.4; Dosage Forms and Strengths section 3

Working with a vial? The reconstitution calculator covers mixing math, not dosing advice.

More reported protocols

Members

Members can compare additional reported doses, schedules, and preparation notes.

Trust & sourcing

  1. Last revieweddone
  2. Next reviewupcoming
US approvalFDA-approved product exists
CompoundingFDA-approved products exist; compounded copies are not FDA approved

Primary sources

The Ultimate Peptides Guide

Spot stronger candidates, weak evidence, and seller red flags before you buy.

Free. Includes evidence and regulatory updates. Unsubscribe anytime.